| MDL | MFCD00866294 |
|---|---|
| Molecular Weight | 565.78 |
| Molecular Formula | C31H55N3O6 |
| SMILES | CCCCCCCCCCCCCCCCCCCCCC(NC(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@H](O2)CO)=NC1=O)=O |
Enocitabine is resistant to deamination because Enocitabine bears a highly lipophilic group at the 4-amino position of the cytosine moiety of cytarabine
[1]
.
The combined effects of Pirarubicin and Enocitabine on HeLa S3 human uterine cervix carcinoma and K562 human myelocytic leukemia cells are determined by enhancement of their cytotoxic activities. Enocitabine or etoposide shows synergistic effects on HeLa S3 and K562 cells
[2]
.
In the presence of Enocitabine, triphosphate forms of the nucleoside analogs are detected in the human cytomegalovirus (HCMV)-infected cells, and synthesis of HCMV DNA is strongly suppressed
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 2 mg/mL ( 3.53 mM ; ultrasonic and warming and heat to 60°C)
H 2 O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7675 mL | 8.8374 mL | 17.6747 mL |
| 5 mM | --- | --- | --- |
| 10 mM | --- | --- | --- |